ENDRA Life Sciences shareholders approve reverse stock split; board sets 1-for-20 ratio

The certified results of the matter voted upon at the meeting, which is more fully described in the definitive proxy statement filed with the Securities and Exchange Commission on October 17, 2022, are as follows: Proposal 1 – The stockholders of the Company approved an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) to effect, at the discretion of the Company’s Board of Directors (the “Board”) on or prior to the one-year anniversary of the date of the Special Meeting, a reverse stock split of the Company’s common stock at a stock split ratio between 1-for-2 and 1-for-30, with the ultimate ratio to be determined by the Board in its sole discretion, the implementation and timing of which shall be subject to the discretion of the Board, with votes cast as follows: For Against Abstain 21,057,265,393 7,433,237,535 5,832,047,971